CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Biomarker
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
    Technologies and Software
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Inventus

Steve Sanghera, Co-Founder and CEO

Knowing the Person Before the Patient: What Comes Next for Clinical Research

Steve Sanghera

Steve Sanghera

Patient Engagement Champion

Bio: Steve Sanghera is co-founder and CEO of Inventus, bringing over 20 years of experience in mobile technology, telecommunications and financial services. He applies his background to clinical research, building purpose-designed technology that improves trial access, reliability and the participant experience.


Clinical trials begin, almost by definition, at the moment someone becomes a patient. Diagnosis comes first, then enrolment, consent and protocol. By the time we meet the person who has become a patient, most of what shaped their health is already out of sight.


The cost of arriving late to the table in terms of understanding the person before they become a patient has a profound impact on clinical trials and the journey they take. Company-sponsored trials grew by roughly a quarter between 2019 and 2024, competing for a finite pool of eligible participants. By most estimates, only a small minority of patients know research is an option in their care. Screen-failure rates in some complex indications run between 50 and 80 percent, and recruitment remains one of the largest costs in late-stage development.


From reactive to proactive


Healthcare more broadly is shifting from treating illness to anticipating it. Prevention, early detection and continuous monitoring are changing how clinicians think about risk. Clinical research should follow. If we understand people earlier, including their routines, baseline physiology, engagement with their own health, and the language and format in which they communicate best, we can design trials around real lives rather than idealized ones.


That matters at every stage. Protocols can be tested against how people live before they are finalized. Feasibility can be judged against real populations rather than registry estimates. And when someone does become eligible, the conversation can start from context rather than a cold screening visit. The aim is fewer wasted screens, better-matched participants and recruitment, and a research experience that feels designed for the individual.


What does knowing the person before they become a patient mean?


Knowing the person before they become a patient does not mean keeping them under surveillance. It means building, with their knowledge and consent, a picture of the signals that matter; activity, sleep, heart-rate trends, medication adherence, communication preferences, and the linguistic, physical and geographic barriers that quietly exclude people from clinical research altogether.


 

Clinical trials work better when we understand people before they become patients, making research more accessible, inclusive and suited to real lives.


Connected devices make this practical. A wearable or home device can generate far more data points in a week than a clinic visit does in a year, and regulators are increasingly open to digital measures as meaningful endpoints. Applied carefully, that data can help identify who might benefit from a study long before a site visit is contemplated, and let sites spend their time on care rather than pre-screening.


Turning the Vision into Reality: The Inventus Approach


At Inventus, our perspective comes from the practical end of the industry. Across hundreds of trials in over 80 countries, we have placed more than half a million devices in patients’ hands, and the lesson has been consistent: technology succeeds only when it fits into a life. The same will be true of a more proactive model.


We believe knowing the person before the patient requires a fundamental shift in how technology supports clinical research. Our ambition is to move beyond simply providing devices for trial participation toward creating an intelligent, connected ecosystem that supports individuals earlier, understands their needs and removes barriers throughout their clinical research journey.


This thinking is central to Inventus 2.0, our next phase of technology innovation, combining purpose-built devices, global connectivity, advanced device management, telehealth and AI-enabled capabilities.


Our next-generation telehealth-centric PD1 patient devices and SD1 site devices are being developed to make clinical research more accessible, proactive and personalized. Enhanced cameras, video capabilities, AI processing and connectivity will enable richer remote patient-clinician interactions, support more sophisticated photographic and video-based assessments, and facilitate the collection of meaningful longitudinal data outside traditional clinical settings.


Importantly, these capabilities could also support the industry’s transition toward prevention and earlier intervention. With appropriate consent, clinical oversight and validated approaches, connected technologies can help establish individual health baselines, identify changes over time and potentially support earlier identification of people who may benefit from participating in relevant clinical research.


For recruitment, the opportunity is equally significant. By reducing geographical, linguistic and technological barriers, while supporting remote screening and engagement, we can help sponsors and research sites reach more diverse populations, improve accessibility and potentially reduce avoidable screening failures.


However, technology must never become another barrier to participation. Our purpose-built approach is designed to ensure patients are not disadvantaged by the devices they own, their digital confidence or where they live.


Ultimately, our ambition is simple: to help clinical research move from understanding patients only when they enter a trial, toward understanding and supporting people throughout their healthcare journey.


Because, the future of clinical research should not simply be more technologically advanced. It should be more human.


No single organization will build this future. It will take sponsors, CROs and technology vendors agreeing on interoperable standards. Above all, it will take participants telling us what they will and won’t accept.


The opportunity for the next decade is to understand people well enough that they are not strangers if they become patients. If we get it right, trials become faster and more representative and care itself becomes more personal. That is a future worth building together.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

For life sciences executives and clinical research leaders, improving trial participation requires understanding individuals before they become patients and addressing barriers that limit research accessibility. Integrating connected devices, longitudinal health data and consent-based digital engagement can help organizations improve recruitment efficiency, strengthen participant diversity and create more personalized clinical research experiences.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    UPS [NYSE:UPS]

    Four Myths about Innovation in Logistics

    Daniel Gagnon, Vice President, Global Healthcare Strategy and Marketing

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent-Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition

  • Willis Towers Watson

    Abivax [EPA: ABVX]

    Leveraging Technological Advancements for Developing Innovative Therapeutics

    Marc de Garidel, CEO and Interim Chairman, Abivax

  • Willis Towers Watson

    Cordlife Group Limited [SGX: P8A]

    Cord Blood Transplantation: A Lifesaving Resource Overview

    Zhu Pengcheng, PhD, Laboratory & Technical Director, Group Lab Operations and David Leung, PhD, FIBMS, MRSB, CBiol, CSci, CQA(ASQ), CLSSBB, Laboratory Director, Cordlife Group Limited, Singapore

{literal}{/literal}
Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/steve-sanghera-nwid-3920.html